About Tonix Pharmaceuticals Holding
Tonix Pharmaceuticals (NASDAQ:TNXP) is a research-driven biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines to improve the lives of patients suffering from central nervous system (CNS) disorders, immunology, rare diseases, and infectious diseases. Dedicated to addressing unmet medical needs, Tonix Pharmaceuticals is actively engaged in developing a diverse portfolio of potential therapeutic solutions. Their projects range from preclinical to phase 3 clinical trials, with objectives to provide groundbreaking treatments for conditions lacking effective medications. The company's mission is to advance healthcare by delivering accessible, effective solutions to those in need, underscoring their commitment to innovation and patient care.
Snapshot
Operations
Produtos e/ou serviços de Tonix Pharmaceuticals Holding
- TNX-102 SL - A sublingual tablet designed for the management of fibromyalgia and PTSD symptoms.
- TNX-1800 - A live replicating vaccine being developed for the prevention of COVID-19.
- TNX-1900 - A potential treatment for chronic migraine prevention, utilizing intranasal administration.
- TNX-1300 - A biologic designed to treat cocaine intoxication by breaking down cocaine in the blood.
equipe executiva do Tonix Pharmaceuticals Holding
- Dr. Seth Lederman M.D.Co-Founder, President, CEO & Chairman
- Mr. Bradley Saenger CPACFO & Treasurer
- Mrs. Jessica Edgar MorrisChief Operating Officer
- Dr. Gregory M. Sullivan M.D.Chief Medical Officer & Secretary
- Ms. Siobhan Fogarty B.Sc., M.Sc.Chief Technical Officer
- Ms. Irina IshakGeneral Counsel
- Dr. Darryl Rideout Ph.D.Executive Vice President of Experimental Chemistry
- Dr. Sina Bavari Ph.D.Executive Vice President of Infectious Disease Research & Development
- Dr. Zeil Rosenberg M.D., M.P.H.Executive Vice President of Medical
- Mr. Thomas Englese M.B.A.Executive Vice President of Commercial Operations